

Lovenox (Preservative Free) - (100, 150 mg/ml;Injectable, Subcutaneous)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | Enoxaparin Sodium | Innovator | Sanofi |
| Dosage | 100, 150 mg/ml;Injectable, Subcutaneous | Branded US Sales | More Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | None |
| Final Approvals | More Than 5 | Generic Launches | More Than 5 |
| Indication | Indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): in patients undergoing abdominal surgery who are at risk for thromboembolic complications | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.